STOCK TITAN

Cosmos Health Inc. - COSM STOCK NEWS

Welcome to our dedicated page for Cosmos Health news (Ticker: COSM), a resource for investors and traders seeking the latest updates and insights on Cosmos Health stock.

Overview of Cosmos Health Inc.

Cosmos Health Inc. (NASDAQ:COSM) is a diversified, vertically integrated global healthcare company specializing in the development, manufacturing, and distribution of nutraceuticals, pharmaceuticals, and over-the-counter (OTC) medicines. Established in 2009 and headquartered in Chicago, Illinois, Cosmos Health operates across multiple business segments, including wholesale drug distribution, proprietary product lines, contract manufacturing, and telehealth services. The company’s vertically integrated model enables it to control every stage of its value chain, from research and development (R&D) to production and global distribution, ensuring high-quality standards and operational efficiency.

Core Business Segments

Nutraceuticals and Proprietary Brands

Cosmos Health is a prominent player in the nutraceuticals market, offering a range of premium products under its proprietary brands, such as Sky Premium Life® and Mediterranation®. These brands are designed to meet the growing demand for health and wellness solutions, with products ranging from dietary supplements to specialized formulations addressing various health needs. The company’s R&D team focuses on creating innovative nutraceuticals, leveraging natural ingredients like Kakadu Plum and advanced formulations such as ZenBlend for relaxation and Skinovate for anti-aging.

Pharmaceuticals and Manufacturing

In the pharmaceutical sector, Cosmos Health provides a comprehensive portfolio of branded generics, OTC medicines, and proprietary complex generics. Its subsidiary, Cana Laboratories S.A., operates under European Good Manufacturing Practices (GMP) and is certified by the European Medicines Agency (EMA). This facility manufactures a wide array of products, including pharmaceuticals, food supplements, cosmetics, and medical devices, ensuring compliance with stringent international quality standards. The company also engages in contract manufacturing for specialty pharmaceutical firms, producing high-demand products such as Baclofen solutions and vitamin B-complex tablets.

Wholesale Distribution

The wholesale segment is a significant revenue driver for Cosmos Health, supplying pharmaceuticals and parapharmaceuticals to retail pharmacies and healthcare providers. With a robust distribution network spanning Europe, Asia, and North America, the company has established itself as a reliable partner for wholesale drug distributors and retail healthcare providers.

Telehealth and Digital Healthcare

Cosmos Health has embraced digital transformation through its telehealth platform, ZipDoctor, Inc. This service offers remote healthcare solutions, catering to the increasing demand for accessible and efficient medical consultations. The integration of telehealth into its business model underscores the company’s commitment to innovation and patient-centric care.

Research and Development (R&D) Initiatives

R&D is a cornerstone of Cosmos Health’s strategy, with a focus on addressing critical health challenges such as obesity, diabetes, cancer, and autoimmune disorders. The company leverages artificial intelligence (AI) through its Cloudscreen platform for drug repurposing, accelerating the development of novel treatments. Recent advancements include patents for anticancer drugs targeting prostate, ovarian, and colorectal cancers, as well as innovative solutions for multiple sclerosis and allergic inflammation.

Global Expansion and Strategic Partnerships

Cosmos Health continues to expand its global footprint through strategic partnerships and distribution agreements. Notable collaborations include exclusive rights to distribute Virax Biolabs’ diagnostic kits in Europe and the Gulf Cooperation Council (GCC) countries. The company’s products are available in leading international retail chains and e-commerce platforms, further solidifying its market presence.

Competitive Positioning

In a competitive healthcare landscape, Cosmos Health differentiates itself through its vertically integrated operations, innovative R&D, and a diverse product portfolio. Its focus on high-margin proprietary brands and strategic geographic expansion positions the company as a growing contender in the global healthcare market.

Conclusion

With a commitment to innovation, quality, and global reach, Cosmos Health Inc. is poised to address some of the most pressing challenges in healthcare. Its diversified business model, coupled with cutting-edge R&D initiatives, ensures a sustainable growth trajectory in the nutraceutical, pharmaceutical, and telehealth sectors.

Rhea-AI Summary

Cosmos Health (NASDAQ:COSM) announced its successful participation in Vitafoods Europe 2024, held from May 14 to May 16 at Palexpo, Switzerland. The event, a premier nutraceutical trade show, attracted over 20,000 attendees, more than 50 speakers, and 1,100+ exhibitors from 160+ countries. Cosmos Health showcased its Sky Premium Life nutraceuticals range, receiving significant interest and positive feedback from industry leaders and potential partners. The company connected with numerous organizations, exploring new trends and building partnerships to expand its global business network. CEO Greg Siokas highlighted the event's success in accelerating business growth and enhancing Cosmos Health's international presence.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.14%
Tags
partnership
-
Rhea-AI Summary
Cosmos Health, a global healthcare group, received a notification from Nasdaq for the late filing of its Form 10-K. The company is currently non-compliant with Nasdaq Listing Rule 5250(c)(1) but has 60 days to submit a plan to regain compliance. The CEO is optimistic about resolving the issue.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.45%
Tags
none
-
Rhea-AI Summary
Cosmos Health Inc. announces the development of Cloudscreen 2.0, an advanced AI drug repurposing platform, following the acquisition of Cloudscreen. The new platform utilizes cutting-edge AI and machine learning technologies to predict drug-protein interactions across the human proteome's structural landscape. By integrating mutagenesis data and prediction tools for disordered proteins, Cloudscreen 2.0 aims to revolutionize drug repurposing with more robust predictions and higher confidence scores. Greg Siokas, CEO of Cosmos Health, anticipates significant positive outcomes from Cloudscreen 2.0.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.73%
Tags
AI
Rhea-AI Summary
Cosmos Health Inc. announces final stages of securing regulatory approval to sell biocide disinfectant hand soap, C-Scrub Wash 4% CHG, in the UK. The Company expects to enter agreements to supply the NHS, targeting a significant market share. C-Scrub offers immediate and prolonged antimicrobial action, catering to a wide range of microbes, with a focus on skin health and cosmetic friendliness. The global hospital disinfectant market is projected to grow significantly, positioning Cosmos Health for potential growth opportunities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.57%
Tags
none
-
Rhea-AI Summary
Cosmos Health Inc. has received regulatory approval to sell its Sky Premium Life vitamins and food supplements in the UAE market, with a projected market growth to $3.94 billion by 2030. The company aims to secure an exclusive distribution agreement and increase revenue through expansion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.27%
Tags
none
-
Rhea-AI Summary
Cosmos Health Inc. announces the successful acquisition of Pharmatrade S.A.'s distribution network, aiming to boost 2024 revenue by $5 million and improve operational efficiencies through synergies with CosmoFarm Pharmaceuticals S.A.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.39%
Tags
Rhea-AI Summary
Cosmos Health Inc. receives a Speculative Buy rating and a $4.00 price target from Taglich Brothers, indicating substantial growth potential. The company's revenue is expected to reach $64 million in FY 2024, with a focus on vertical integration and global expansion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.12%
Tags
-
Rhea-AI Summary
Cosmos Health Inc. CEO, Mr. Greg Siokas, demonstrates his confidence in the company by acquiring 60,000 shares at $0.8301 each, totaling $49,806. Siokas plans to invest up to $3 million in shares by 2024. Despite significant company progress, Siokas believes the stock is undervalued, emphasizing commitment to enhancing shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
none
-
Rhea-AI Summary
Cosmos Health Inc. announced that Taglich Brothers, Inc. has initiated coverage of the Company's common stock. Taglich Brothers is a full-service broker dealer with a focus on microcap companies. The coverage and associated reports will be available at www.taglichbrothers.com. Cosmos Health CEO, Greg Siokas, stated that the company has accomplished multiple milestones, including transforming its balance sheet, completing strategic acquisitions, enhancing production facilities, launching new brands, filing patent applications, and establishing a portfolio of generic drugs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.5%
Tags
none
Rhea-AI Summary
Cosmos Health Inc. has successfully completed the acquisition of Cloudscreen, a cutting-edge AI-powered platform specialized in drug repurposing. Cloudscreen's AI algorithm integrates 1D and 3D data to provide accurate predictions for existing drugs towards new indications, offering higher success rates, heightened safety profiles, and significantly shorter impact times compared to traditional drug development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.96%
Tags

FAQ

What is the current stock price of Cosmos Health (COSM)?

The current stock price of Cosmos Health (COSM) is $0.3504 as of April 4, 2025.

What is the market cap of Cosmos Health (COSM)?

The market cap of Cosmos Health (COSM) is approximately 8.7M.

What does Cosmos Health Inc. specialize in?

Cosmos Health Inc. specializes in nutraceuticals, pharmaceuticals, and telehealth, offering proprietary brands and innovative healthcare solutions.

How does Cosmos Health generate revenue?

The company generates revenue through wholesale drug distribution, proprietary product sales, contract manufacturing, and telehealth services.

What are some of Cosmos Health’s proprietary brands?

Key proprietary brands include Sky Premium Life® and Mediterranation®, focusing on high-quality nutraceuticals and wellness products.

What is Cosmos Health’s approach to R&D?

The company leverages AI-driven drug repurposing and innovative research to develop treatments for conditions like cancer, obesity, and autoimmune disorders.

Where does Cosmos Health operate?

Cosmos Health has a global presence, with operations in Europe, Asia, and North America, and distribution centers in Greece and the UK.

What makes Cosmos Health unique in the healthcare industry?

Its vertically integrated model, innovative R&D initiatives, and focus on high-margin proprietary brands set it apart in the competitive healthcare market.

What is the role of AI in Cosmos Health’s operations?

Cosmos Health uses AI through its Cloudscreen platform to accelerate drug repurposing and enhance the development of novel treatments.

What are some recent advancements by Cosmos Health?

Recent advancements include patents for anticancer drugs, a weight management solution, and expansion into telehealth through ZipDoctor.
Cosmos Health Inc.

Nasdaq:COSM

COSM Rankings

COSM Stock Data

8.66M
16.36M
29.66%
6.97%
3.46%
Medical Distribution
Wholesale-drugs, Proprietaries & Druggists' Sundries
Link
United States
THESSALONIKI